About Dr. Cheng Wenwu
Dr. Cheng Wenwu (成文武) is a Professor, Doctoral Supervisor, and one of China's leading gynecological oncologists specializing in endometrial cancer, ovarian cancer, and cervical cancer, based at the Department of Gynecological Oncology, Fudan University Shanghai Cancer Center (FUSCC). With extensive clinical and research expertise in the surgical and systemic management of gynecological malignancies — with particular focus on endometrial cancer molecular classification, fertility-sparing management of early endometrial cancer, and the integration of immunotherapy and targeted therapy into gynecological cancer treatment — Dr. Cheng is recognized as a senior authority in gynecological oncology at China's foremost dedicated cancer center.
Endometrial cancer is the most common gynecological malignancy in developed countries and is rapidly increasing in incidence in China, driven by rising rates of obesity, metabolic syndrome, and an aging population. The management of endometrial cancer has been transformed over the past decade by the development of the TCGA molecular classification system — which divides endometrial cancer into four prognostic subgroups (POLE-ultramutated, MMR-deficient/MSI-high, copy-number-low/p53 wild-type, and copy-number-high/p53-abnormal) with distinct biological behavior, treatment sensitivity, and prognosis — and by the demonstration that immune checkpoint inhibitors (pembrolizumab, dostarlimab) produce dramatic and durable responses in MMR-deficient/MSI-high endometrial cancer. Dr. Cheng's clinical practice at FUSCC — supported by the center's comprehensive molecular profiling capabilities and multidisciplinary gynecological oncology team — provides international patients with access to the most current evidence-based, molecularly guided endometrial cancer management available in China.
Hospital Affiliation: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center (FUSCC) is China's foremost dedicated cancer center. Its Department of Gynecological Oncology is one of the highest-volume gynecological cancer programs in China, managing hundreds of new cases of endometrial cancer, ovarian cancer, and cervical cancer annually. The department's gynecological oncology multidisciplinary team integrates gynecological surgery, medical oncology, radiation oncology, pathology, and radiology for comprehensive gynecological cancer management. Its molecular pathology laboratory provides TCGA molecular classification of endometrial cancer including POLE mutation analysis, MMR protein IHC and MSI testing, p53 IHC, and copy number analysis — enabling the molecularly guided treatment stratification that is the foundation of modern endometrial cancer management.
Clinical Specialties: What Dr. Cheng Wenwu Treats
- Endometrial cancer surgery and molecular classification — total hysterectomy and bilateral salpingo-oophorectomy (TH-BSO) with pelvic and para-aortic lymphadenectomy for endometrial cancer; laparoscopic and robotic minimally invasive hysterectomy; sentinel lymph node mapping and biopsy for early endometrial cancer; TCGA molecular classification including POLE mutation analysis, MMR IHC and MSI testing, p53 IHC, and copy number profiling; risk stratification using ESGO/ESTRO/ESP 2021 guidelines based on molecular subgroup, grade, and stage; adjuvant treatment selection based on molecular risk group
- Fertility-sparing management of early endometrial cancer — progestin therapy (medroxyprogesterone acetate, megestrol acetate, levonorgestrel IUD) for grade 1 endometrioid endometrial cancer confined to the endometrium in women wishing to preserve fertility; hysteroscopic resection of endometrial cancer with concurrent progestin therapy; response assessment by hysteroscopy and endometrial biopsy; assisted reproduction coordination after complete response; close surveillance for recurrence after fertility-sparing treatment
- Advanced and recurrent endometrial cancer — pembrolizumab plus lenvatinib for MMR-proficient advanced or recurrent endometrial cancer (KEYNOTE-775); dostarlimab or pembrolizumab monotherapy for MMR-deficient/MSI-high advanced or recurrent endometrial cancer; carboplatin/paclitaxel chemotherapy for advanced endometrial cancer; hormonal therapy with aromatase inhibitors and progestins for hormone receptor-positive recurrent endometrial cancer; targeted therapy with mTOR inhibitors (everolimus, temsirolimus) for recurrent endometrial cancer; HER2-targeted therapy for HER2-amplified serous endometrial cancer
- Ovarian cancer surgery and management — primary debulking surgery (PDS) for advanced ovarian cancer with goal of complete gross resection (R0); interval debulking surgery (IDS) after neoadjuvant chemotherapy for patients not suitable for upfront PDS; secondary cytoreduction for platinum-sensitive recurrent ovarian cancer; BRCA1/2 germline and somatic testing for all ovarian cancer patients; PARP inhibitor maintenance therapy (olaparib, niraparib, rucaparib) after first-line platinum-based chemotherapy; bevacizumab plus chemotherapy and bevacizumab maintenance for advanced ovarian cancer; management of platinum-resistant recurrent ovarian cancer
- Cervical cancer surgery and management — radical hysterectomy (type III) with pelvic lymphadenectomy for early-stage cervical cancer; laparoscopic and robotic radical hysterectomy; fertility-sparing radical trachelectomy for selected early-stage cervical cancer patients wishing to preserve fertility; coordination with radiation oncology for definitive chemoradiotherapy for locally advanced cervical cancer; pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826)
- Hereditary gynecological cancer — BRCA1/2 germline testing for ovarian cancer patients and high-risk individuals; Lynch syndrome evaluation for endometrial cancer patients with MMR deficiency; risk-reducing salpingo-oophorectomy (RRSO) for BRCA1/2 mutation carriers; surveillance and risk management for Lynch syndrome-associated gynecological cancer risk; genetic counseling coordination and family cascade testing
Why International Patients Choose Dr. Cheng Wenwu and FUSCC
International patients seek gynecological oncology consultation with Dr. Cheng Wenwu and FUSCC for reasons that reflect both the clinical depth of his expertise in molecularly guided endometrial cancer management and the comprehensive gynecological oncology infrastructure available at China's foremost cancer center.
For patients with endometrial cancer who have not undergone TCGA molecular classification — which is not yet standard practice at many institutions worldwide — Dr. Cheng's systematic approach to molecular subtyping provides the prognostic and predictive information that is essential for optimal adjuvant treatment selection. The identification of MMR deficiency — which predicts exceptional sensitivity to immune checkpoint inhibitors — or POLE ultramutation — which identifies a group with excellent prognosis that may not require adjuvant treatment — can fundamentally change the management approach and spare patients unnecessary treatment toxicity or ensure they receive the most effective available therapy.
For young women with early endometrial cancer who wish to preserve fertility, Dr. Cheng's expertise in fertility-sparing progestin therapy and hysteroscopic management provides access to a carefully monitored conservative approach that may enable future pregnancy while maintaining oncological safety — an approach that requires the close surveillance and multidisciplinary coordination that is available at only a small number of specialized gynecological oncology centers.
The cost of gynecological oncology consultation and surgery at FUSCC is substantially below that of equivalent care in Western healthcare systems, and access to specialist consultation can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Cheng Wenwu at FUSCC arranged through CMCS begin with a comprehensive review of all prior gynecological oncology records — including pathology reports and molecular profiling results (MMR IHC, MSI, POLE, p53), staging imaging (MRI pelvis, CT chest/abdomen/pelvis, PET-CT), CA-125 and other tumor marker trends, prior surgical records, and prior systemic therapy and radiotherapy records. CMCS will arrange certified translation of all medical records and imaging reports in advance of the consultation. Dr. Cheng will assess the tumor histology, molecular subgroup, and stage, evaluate surgical and systemic treatment options, outline the recommended management strategy with detailed rationale, and coordinate multidisciplinary tumor board review. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Cheng's team and the patient's home gynecological oncologist for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking gynecological oncology consultation with Dr. Cheng Wenwu at Fudan University Shanghai Cancer Center. Our services include priority consultation scheduling, certified medical record and pathology report translation, coordination of molecular profiling and staging investigations, on-site interpretation, surgical logistics and hospital admission coordination, and written English-language reporting of all findings and recommendations.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
댓글 0개